作者: Nabeel Shalan , Paulo M. Hoff
DOI: 10.1007/978-1-59745-215-1_6
关键词:
摘要: The epidermal growth factor receptor (EGFR), also known as the ErbB1 or HER1 receptor, triggers intricate and interrelated downstream signaling pathways that, when deregulated, can lead to malignant transformation. EGFR has now become validated a target for anticancer therapy, with both small-molecule tyrosine kinase inhibitors monoclonal antibodies showing clinical activity in some cancers. biology of data supporting its use colorectal cancer are explored this chapter.